TRANSFORMED NON-HODGKIN LYMPHOMA
Clinical trials for TRANSFORMED NON-HODGKIN LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new TRANSFORMED NON-HODGKIN LYMPHOMA trials appear
Sign up with your email to follow new studies for TRANSFORMED NON-HODGKIN LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for Tough-to-Treat lymphoma: trial tests Next-Gen cell therapy
Disease control Recruiting nowThis trial is testing a new, experimental CAR-T cell therapy called WZTL-002 for people with aggressive large B-cell lymphoma that has returned or not responded to standard chemotherapy. The main goals are to see how well the therapy works to eliminate the cancer and to understan…
Matched conditions: TRANSFORMED NON-HODGKIN LYMPHOMA
Phase: PHASE2 • Sponsor: Malaghan Institute of Medical Research • Aim: Disease control
Last updated Mar 31, 2026 12:12 UTC
-
Double-Punch immune therapy aims to stop Lymphoma's return
Disease control Recruiting nowThis early-stage study is testing a two-part treatment to prevent aggressive B-cell lymphoma from coming back after a stem cell transplant. Doctors take a patient's own immune cells, modify them to target cancer, and infuse them back. They then give a vaccine designed to boost th…
Matched conditions: TRANSFORMED NON-HODGKIN LYMPHOMA
Phase: PHASE1 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Mar 30, 2026 14:30 UTC
-
Scientists test double punch against Tough-to-Treat blood cancer
Disease control Recruiting nowThis study is testing whether adding one of two new drugs (tazemetostat or zanubrutinib) to an existing two-drug therapy works better for controlling an aggressive type of blood cancer called large B-cell lymphoma. It is for adults whose cancer has returned or did not respond to …
Matched conditions: TRANSFORMED NON-HODGKIN LYMPHOMA
Phase: PHASE2 • Sponsor: SWOG Cancer Research Network • Aim: Disease control
Last updated Mar 24, 2026 12:02 UTC